Cancer cells possess traits reminiscent of those ascribed to normal stem cells. It is unclear, however, whether these phenotypic similarities reflect the activity of common molecular pathways. Here, we analyze the enrichment patterns of gene sets associated with embryonic stem (ES) cell identity in the expression profiles of various human tumor types. We find that histologically poorly differentiated tumors show preferential overexpression of genes normally enriched in ES cells, combined with preferential repression of Polycomb-regulated genes. Moreover, activation targets of Nanog, Oct4, Sox2 and c-Myc are more frequently overexpressed in poorly differentiated tumors than in well-differentiated tumors. In breast cancers, this ES-like signature is associated with high-grade estrogen receptor (ER)-negative tumors, often of the basal-like subtype, and with poor clinical outcome. The ES signature is also present in poorly differentiated glioblastomas and bladder carcinomas. We identify a subset of ES cell-associated transcription regulators that are highly expressed in poorly differentiated tumors. Our results reveal a previously unknown link between genes associated with ES cell identity and the histopathological traits of tumors and support the possibility that these genes contribute to stem cell-like phenotypes shown by many tumors.
The apparent parallels between tumor cells and normal stem cells have generated great interest in the possible links between these two classes of cells. The hallmark traits of stem cells-self-renewal and differentiation capacity-are mirrored by the high proliferative capacity and phenotypic plasticity of tumor cells 1 . Moreover, tumor cells often lack the terminal differentiation traits possessed by their normal counterparts. These parallels have given rise to the hypothesis that tumors often arise from undifferentiated stem or progenitor cells or, alternatively, that cancer cells can undergo progressive de-differentiation during their development [1] [2] [3] . Additionally, some have proposed that cancer stem cells-a subpopulation of cancer cells possessing tumor-initiating capability-are derived from normal stem cells 1, 4 . Although certain regulators of stem cell function have been implicated in cancer pathogenesis 2 , a broad description of the activity of stem cell-associated regulatory networks in tumors is lacking.
The differentiation level (or grade) of human tumors is assessed routinely in the clinic, with poorly differentiated tumors generally having the worst prognoses. However, this classification is based on histopathological criteria, and the underlying molecular pathways controlling tumor differentiation are poorly described. Moreover, it is not known whether a lack of histological differentiation markers in tumor cells reflects the possession of stem cell-like traits. A number of oncogenes are known to interfere with normal cell differentiation, myc being a notable example 5, 6 , and such oncogenes could also affect tumor cell differentiation. The recent demonstration that adult fibroblasts can be reprogrammed into pluripotent ES-like cells 7, 8 raises the possibility that the combined expression of stem cell-associated factors and specific oncogenes could also induce a nondifferentiated state in cancer cells. In fact, ectopic expression of Oct4, a central determinant of ES cell identity, is sufficient to induce tumor growth in the adult mouse 9 , and Polycomb complex components central to stem cell function, such as Bmi1 and Ezh2, are also oncogenic 10 .
These observations suggest that the regulatory networks controlling the function of stem cells may also be active in certain tumors. These networks have been the focus of much recent interest, and progress has been made particularly in the study of ES cells 11 . Current evidence indicates that some of the key regulators of ES cell identity-Oct4, Sox2 and Nanog-are expressed only in specific human cancer types [12] [13] [14] [15] . Nevertheless, it is conceivable that different regulators, possibly paralogs of these ES cell factors, may activate stem-cell regulatory networks in other tumor types. Detection of the activity of such complex networks must rely on expression analysis of many genes in multiple cancer samples, rather than on the presence or absence of individual factors 16, 17 .
Here, we use recently developed gene set expression analysis methods 18 to assess whether the expression signatures and regulatory networks that define human ES cell identity are also active in human tumors. Our results identify previously undescribed links between tumor pathogenesis and the ES cell state.
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in ES cells are also active in tumors. As different subsets of the many genes involved in these networks may be active in different individual tumors, we reasoned that expression analyses of gene sets (groups of genes related through a common function, pathway or other property) could prove more revealing than single-gene analyses 16, 17, 19 . Accordingly, we set out to collect gene sets that represent the core expression signature of ES cells and that reflect the activity of the regulatory pathways associated with their identity. We extracted these sets directly from published studies without modifying their contents. In order to eliminate effects of interspecies differences 20, 21 , we used only gene sets identified in human cells.
We compiled 13 partially overlapping gene sets, which fall into four groups ( Table 1 and Supplementary Table 1 online): (i) ES expressed genes: two sets of genes overexpressed in ES cells compared to other cells and tissues according to a multistudy compilation and meta-analysis 22 ; (ii) Nanog, Oct4 and Sox2 (NOS) targets: four sets of genes whose promoters are bound and activated in human ES cells by each of these regulators of ES cell identity, or co-activated by all three 23 , and an additional set (NOS TFs) including a subset of NOS activation targets encoding transcription regulators; (iii) Polycomb targets: four sets representing genes bound by the Polycomb repressive complex 2 (PRC2) in human ES cells 24 ; and (iv) Myc targets: two sets of genes bound and activated by c-Myc, identified in two independent studies 25, 26 . We hypothesized that these 13 gene sets would allow the definition of an ES-cell expression signature and, in turn, the detection of this signature in tumors.
Establishment of an ES cell gene-set enrichment pattern
We used a recently described computational strategy to assess the expression pattern of the above gene sets in microarray expression data 18 . This method tests whether the genes that are over-or underexpressed in each profiled tissue or cell line include a higher-than-randomly-expected fraction of genes from a particular gene set (Fig. 1a) . A second analysis step determines whether particular sample groups (for example, all ES cell samples) preferentially over-or underexpress particular gene sets (Fig. 1a) .
We first analyzed the enrichment patterns of the 13 gene sets in an expression profile dataset that included 5 human ES lines, 7 embryonic carcinoma (EC) lines and various other normal and tumorigenic cells and tissues 27 . We found that the various ES-expressed and NOS-target gene sets were, as anticipated, preferentially overexpressed in the ES and EC samples, whereas the Polycomb-target sets were underexpressed in these samples (Fig. 1b) . The highest levels of gene set enrichment were observed for the ES exp1 set (P values ranging from 10 −28 to 10 −53 in individual ES lines), which includes 380 genes shown to be overexpressed in ES cells in five profiling studies or more 22 . Myc-target gene sets showed lower enrichment levels in the ES lines. Normal testis samples and normal cultured cells showed an enrichment pattern opposite to that of ES cells, whereas the various tumor cell lines did not show a consistent gene set enrichment pattern (Fig. 1b) . These findings were also evident in the sample-group analysis (Fig. 1c) . The NOS TFs set was the only set enriched in the male germ-cell tumor group (Fig. 1b,c) , despite the fact that only half of the genes in this small set were included in the arrays used in this study 27 . This finding corresponds to the known activity of ES cell-associated transcription regulators in germ-cell tumors 12, 13 .
These analyses indicated that the combined enrichment pattern of the 13 gene sets can be viewed as a gene set-based expression signature and that a specific enrichment pattern (signature) associated with ES cell identity can be defined.
ES-like signature in poorly differentiated tumors
We proceeded to test whether the ES-associated gene sets were enriched in human tumors. We generated a compendium of data from six published studies of breast cancer expression profiles [28] [29] [30] [31] [32] [33] comprising a total of 1,211 tumors (Supplementary Table 2 online). Available tumor annotations were derived from the original publications and included tumor grade, size, ER expression, metastasis to lymph nodes or to distant organs and disease-associated mortality.
We analyzed the enrichment patterns of the 13 gene sets across the compendium samples. Notably, poorly differentiated (grade 3) breast tumors showed an enrichment pattern resembling that observed in ChIP array of Nanog in hES cells; activated genes 23 ChIP array of Oct4 in hES cells; activated genes 23 ChIP array of Sox2 in hES cells; activated genes 23 Overlap of above three sets 23 Transcription regulators in NOS targets set 23 Polycomb ChIP array of Suz12 in hES cells 24 ChIP array of Eed in hES cells 24 ChIP array of trimethlyated H3K27 in hES cells 24 Overlap of three above sets 24 Myc targets Myc targets1
Myc targets2 230
775
ChIP array of c-Myc in cultured cell lines, focusing on E-box-containing genes; high affinity bound subset 25 ChIP array of c-Myc and of Max in a Burkitt's lymphoma cell line; overlap set 26 Listed in four groups are 13 partially overlapping gene sets that were used in this study. The 'Source' column indicates the method by which these gene sets were obtained in the original studies. ChIP, chromatin immunoprecipitation.
ES cells. This included underexpression of Polycomb target gene sets and overexpression of ES-expressed sets, Myc-target gene sets and some of the NOS-target gene sets (Fig. 2a,b) . Conversely, the well-differentiated (grade 1) tumors showed an opposite pattern. The most significant degrees of enrichment were observed for the ES-expressed and Polycomb-target sets (P = 10 −13 to P = 10 −50 for sample-group enrichments in grade 3 tumors; Fig. 2b ). The NOS TFs gene set was among those enriched in high-grade breast cancers (P = 6.3 × 10 −5 ). We observed this overall enrichment pattern with limited variation when analyzing the individual studies comprising the compendium separately (data not shown).
These findings indicate that tumors that are defined as poorly differentiated according to purely histopathological criteria in fact show a molecular similarity to ES cells, as reflected by the coordinated up-or downregulation of gene sets associated with ES cell identity. This similarity suggests that the neoplastic cells within such tumors are closer in their traits to normal undifferentiated stem cells than are cells in welldifferentiated tumors.
Specific breast cancer subclasses possess the ES signature
We examined whether enrichments of the 13 gene sets would be observed when the breast tumors in our compendium were stratified according to criteria other than tumor grade. Our analysis indicated that tumors lacking expression of the estrogen receptor (ER-negative) showed an ES-like enrichment pattern when compared to the receptor-expressing (ER-positive) tumors (Figs. 2a and 3a) . Most estrogen receptor-negative tumors are poorly differentiated, indicating an overlap between these two categories. We therefore analyzed gene-set enrichments in the tumors stratified into six groups representing all possible combinations of these two parameters (Fig. 3b) . This analysis indicated that, even within the same ER status, high-grade tumors were more ES-like in their enrichment pattern than were low-grade tumors; similarly, ER-negative tumors within the same grade were more ES-like than their ER-positive counterparts (Fig. 3b) . The ES signature is thus independently associated with both tumor grade and ER status with grade 3, ER-negative tumors showing the overall most significant gene-set enrichments. Subtraction of genes closely associated with ER status did not significantly affect this enrichment pattern (data not shown).
We also found that tumors of larger size at the time of diagnosis (more than 2 cm diameter) were more likely to possess the ES signature compared to smaller tumors, even within a given grade (Fig. 3a,b) . This finding could suggest that tumors de-differentiate as they grow; alternatively, it is possible that poorly differentiated tumors are initially detected at larger sizes because of their enhanced growth rates.
Several 'intrinsic subtypes' of breast cancer have been previously defined on the basis of tumor expression profiles: normal-like, luminal type A, luminal type B, HER2-like and basal-like 34, 35 . We classified the tumors in our compendium using this method and then tested whether the 13 gene sets showed enrichments in particular subtypes. The basal-like tumors showed an ES-like signature with highly significant gene-set enrichments (Fig. 3a) , whereas at the other extreme, luminal type A tumors showed the opposite pattern. Basal-like tumors are mostly grade 3 and lack expression of the estrogen receptor, possessing a high proliferation rate and a high nucleus-to-cytoplasm volume ratio 36, 37 . Recent histological analysis has shown that these tumors often express markers of both the luminal and the myoepithelial (basal) lineages present in the normal mammary duct 37 , suggesting that they arise from a still-unidentified, mammary stem or progenitor cell 3 . The association between the basal-like subtype and the ES signature suggests that, compared with other breast cancer subtypes, these basaloid tumors may possess traits rendering them more similar to normal stem cells.
The ES signature is associated with poor prognosis
Analysis of gene-set enrichments in the breast tumors stratified according to clinical progression parameters (lymph node and distant metastasis, overall survival) indicated only weak associations of the ES-associated sets with poor outcome (Fig. 3c) . To assess whether presence of the ES signature is associated with poor prognosis in a more detailed manner, we performed Kaplan-Meier analyses of overall survival for individuals 18 . For each sample (array), genes over-and underexpressed relative to the mean across samples are scored. The fraction of these differentially expressed genes that belong to each of the tested gene sets is then calculated, and its significance over random is estimated, producing a P value. In the second step of the analysis, the overrepresentation of particular sample groups among the samples enriched for each gene set is assessed. (b) Gene-set enrichments in ES cells compared to other cell types. Columns represent individual samples (sample annotations on bottom); sample group names are indicated above. Rows represent individual gene sets (names indicated on left). Red, gene-set enrichment for overexpression; green, gene-set enrichment for underexpression; black, no significant enrichment. (c) Enrichment pattern across sample groups. Numbers indicate P values for gene-set enrichment significance within sample group in negative log (for example, 4 indicates P = 10 −4 ).
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with breast cancer included in five independent studies 28, 30, 31, 33, 38 .
Tumors that showed both overexpression of the ES exp1 set and underexpression of the PRC2 targets set were labeled as possessing the ES signature for this purpose. Individuals bearing tumors with this signature had worse survival rates than the remaining individuals with breast cancer, with significance levels varying from study to study (Fig. 3d) . A meta-analysis of survival data from the five studies together indicated that the mortality rate of individuals bearing tumors with the ES signature was significantly higher (P < 0.0001), with a hazard ratio of 2.03 ( Supplementary Fig. 1 online) . This analysis also indicated that the ES signature provides prognostic information beyond that provided by tumor grade and is predictive of poor outcome even when individuals bearing tumors of the basal-like subtype are excluded. Thus, possession of the ES signature correlates with aggressive tumor behavior.
The ES signature is not a direct reflection of proliferation rates
Breast cancer grade is determined using metrics for duct formation, nuclear atypia and mitotic index; poorly differentiated tumors therefore often contain more proliferating cells than do well-differentiated tumors. As ES cells are characterized by a high proliferation rate 39 , we wished to assess the contribution of proliferation-related genes to the observed gene-set enrichments. We collected three different sets of proliferation genes (Supplementary Table 3 online): genes functionally involved in proliferation (according to Gene Ontology (GO) annotations), genes showing cell cycle stage-specific expression 40 , and genes belonging to a 'proliferation cluster' defined in human breast tumor expression data 35 . We first examined the enrichment pattern of these sets in ES cells relative to other cell types. The proliferation-associated sets were overexpressed in ES and EC cell lines and also in most cultured tumor cell lines (Fig. 4a) . This enrichment pattern contrasted with that shown by the ES gene sets, which were not overexpressed in the tumor cell lines despite the rapid proliferation of the latter (Fig. 4a) . This finding indicates that the ES gene sets specifically reflect an ES-like phenotype, rather than a general state of rapid proliferation Next, we generated three amended versions of our original gene sets, removing genes included in each of the proliferation sets. Analysis of the enrichment patterns of the modified gene sets indicated that most of the sets still showed highly significant enrichments ( Fig. 4b and  Supplementary Fig. 2a,b online) ; thus, the ES signature can be detected in high-grade, ER-negative and basal tumors even without the influence of proliferation-associated genes. However, for some gene sets, including the Nanog targets, Oct4 targets and Sox2 targets, the association with tumor grade was dependent to a greater extent on the inclusion of proliferation genes ( Fig. 4b and Supplementary Fig. 2a,b) .
Lastly, we extracted subsets of genes from the ES exp1 gene set, each associated with a specific cellular function, according to GO annotations (Fig. 4c) . Notably, in addition to the 'cell cycle' subset, all other functional subsets tested were also significantly overexpressed in high-grade cancers as well (Fig. 4c) . These combined results indicate that although proliferation-related genes are an inherent part of the ES signature, many other genes, involved in a variety of other distinct cellular functions, also contribute to this signature and to its enrichment in specific tumors.
The ES signature is detected in cancers of various types
We examined whether the ES signature was present in tumors arising in tissues other than the breast. We analyzed the expression profiles of 157 gliomas 41 and found a marked correlation between tumor grade and the presence of the ES-like signature (Fig. 5a ): grade 4 glioblastomas, which represent the most aggressive subtype of glioma, showed significant geneset enrichments corresponding to the ES signature, whereas the other glioma types included in this study (oligodendrogliomas and astrocytomas of grades 2 and 3) showed a lower degree of enrichment for this signature in a manner that correlated with their lower grades. Normal brain tissue showed opposite enrichments (Fig. 5a) comparison is difficult in this case because of the sampling of multiple distinct cell types. We also analyzed an expression dataset of bladder carcinomas, which included normal urinary tract samples as well as grade 2 and 3 transitional cell carcinomas 42 . Here as well, the high-grade tumors showed an ES-like gene set enrichment pattern (Fig. 5b) . Other parameters, such as superficial versus invasive, did not show a strong correlation with the presence or absence of the ES signature (Fig. 5b) . Together, these results indicate that an ES-like signature is present in poorly differentiated cancers arising in various tissues from distinct cells-of-origin.
The ES signature and breast cancer stem cells Cancer stem cells, a subfraction of neoplastic cells possessing tumor-initiating capability, have recently been described in solid and hematopoietic tumors 4 . In breast cancers, a CD44 high /CD24 low tumor-initiating population has been identified, and the expression profiles of this population and of the non-tumor-initiating population (from three individual tumors) have recently been reported 43 . As cancer stem cells have been suggested to possess stem cell-like traits 3, 4 we examined the behavior of the ES gene sets in these samples. The ES signature was not consistently associated with either the tumor-initiating or the non-tumor-initiating population ( Supplementary Fig. 3 online) . This finding does not support a notion by which the ES signature observed in high-grade tumors is a consequence of a higher fraction of CD44 high /CD24 low cells present in these tumors.
However, the small number of samples in this study does not allow definitive conclusions. We noted that the CD24 gene is in fact highly expressed in ES cells 22 and is also preferentially expressed in poorly differentiated, estrogen receptor-negative breast tumors (Supplementary Fig. 4c online) .
ES transcription regulators in poorly differentiated tumors
We hypothesized that among the genes expressed in ES cells, those encoding transcription regulators could provide an important contribution to tumor phenotypes. To identify such candidates, we extracted 68 genes encoding transcription regulators from the two ES exp sets and the NOS TFs set (Supplementary Table 4 online) . Hierarchical clustering across our breast cancer compendium showed that a subset of nine of these genes were preferentially and coordinately overexpressed in the high-grade, ER-negative tumors (Fig. 6a,b and Supplementary Fig. 4a,b) . Notably, this 'Core 9' subset included several genes previously associated with adult stem or progenitor function, ES and tumor cell proliferation and/or cancer progression. These included KLF5, which can replace KLF4 in somatic cell reprogramming 44 , TCF7L1, the ortholog of mouse Tcf3, which plays a pivotal role in skin stem cells 45 , and TEAD4, a co-factor of Yap1 in Hippo pathway signaling 46 .
Examination of the enrichment pattern of the Core 9 genes, defined as a distinct gene set, indicated that they were preferentially overexpressed not only in high-grade, estrogen receptor-negative and basal-like breast cancers (Fig. 6c) carcinomas (Fig. 6d,e) . These findings indicate that specific transcriptional regulators normally active in ES cells are often overexpressed in poorly differentiated tumors arising in distinct tissues. We noted that the known central regulators of ES identity-Nanog, Oct4 and Sox2, as well as Stat3 and Lin28-were not broadly expressed in high-grade breast cancers (Supplementary Fig. 4a) . We next ranked all the genes encoding known and putative transcription regulators in the human genome by the degree of correlation of their expression with that of the Core 9 genes in the breast cancer compendium. The top-ranked 100 genes (Supplementary Table 5 online) were enriched in high-grade cancers (Fig. 6c-f) . These highly correlated genes included members of families encoding developmental regulators, such as Sox and Ets-domain proteins, as well as factors associated with proliferation, such as E2F1, c-Myc and FoxM1. Notably, the Polycomb complex components Ezh2 and Eed were also included in this list, indicating that high Polycomb activity goes hand in hand with expression of ES-associated transcription factors and providing a possible mechanism for the increased repression of Polycomb targets observed in high-grade tumors. We suggest that the combined activity of these regulators contributes to generating a poorly differentiated state in tumors.
DISCUSSION
The relationship between neoplastic cells and normal stem cells is a question of great current interest. Some have postulated that the pathways conferring self-renewal capacity on normal stem cells may carry out a similar function in cancer cells 1 . Examples of such appropriation of specific stem cell-associated regulators and signaling pathways by tumors have been described 1, 2 . Here, we attempted to provide a broad view of the presence of molecular imprints of stemness in cancer by examining the activity of gene sets associated with human ES cell identity in human tumors. Our analyses demonstrate an inverse relationship between the presence of an ES-like gene-set enrichment signature in tumors and the degree of tumor differentiation. This finding is noteworthy, as tumor differentiation (grade) is defined by histopathological criteria, and it was unclear whether the absence of well-differentiated tissue traits would also entail a molecular similarity to an undifferentiated stem cell state. Viewed from the perspective of global gene expression patterns, our results indicate that this indeed is the case.
The association of the ES signature with highgrade tumors arising in distinct tissues is also notable. In the breast and brain, this signature was detected in tumor subtypes previously suggested to arise from oligopotent stem or progenitor cells 37, 47 . As most normal adult stem cells are poorly characterized at present, we were unable to assess the similarity in gene expression profiles between such stem cells and ES cells. Moreover, we cannot definitively determine whether the ES signature is inherited from a stem cell-of-origin or is reactivated during the course of tumor progression.
Various parameters affected our ability to associate gene-set enrichments with specific tumor subtypes within expression datasets; these included the number of samples profiled, the tumor subtypes included and the clinical information available. The substantial amount of data that has been collected for breast cancers allowed us to derive the most definitive conclusions regarding this tumor type. Whether additional cancer types also possess the ES signature must be determined in future studies.
Proliferative capacity and the ability to self renew are integral aspects of adult and embryonic stem cell identity. Distinct cell-cycle regulation mechanisms seem to control the high proliferation rate and truncated G1 phase typical of ES cells 39 . Accordingly, it is clear that genes associated with proliferation contribute to the ES signature described here and to its detection in specific tumors. The separation of proliferation from stemness is difficult, as exemplified by the dual roles of regulators such as Myc and β-catenin in both proliferation and differentiation. However, our results indicate that the combined expression patterns of the multiple genes within the analyzed gene sets reflect a complex ES-like phenotype that goes beyond a general state of proliferation. Moreover, our findings may reflect a similarity in cell-cycle regulation between ES and cancer cells.
Breast cancer cells clearly differ from ES cells in multiple traits and do not possess their pluripotent ability; we could not infer in detail from our gene sets which specific properties are shared between ES and cancer cells. Among the activation targets of Nanog, Oct4 and Sox2, genes encoding transcription regulators were most consistently activated in high-grade breast tumors. Notably, in germ-cell tumors, which are considered closer to ES cells and often do express the NOS factors 12, 13, 27 , it is also the transcription factor-encoding NOS targets that are preferentially overexpressed. These genes may therefore represent the core of the regulatory network controlled by the NOS factors.
We identify a subgroup of transcription regulators that are highly (but not exclusively) expressed in ES cells and that are preferentially expressed in high-grade tumors. Several of these genes are known to also function in adult stem or progenitor cells. We suggest that the degree of tumor differentiation is determined, at least in part, by the concerted activity of these factors and, in addition, that this activity contributes to aggressive tumor behavior. Further functional studies will be necessary to determine the roles of specific regulators in generating stem-like tumor phenotypes. In the longer term, detailed characterization of the stem-cell regulatory networks active in cancer is likely to yield powerful diagnostic and prognostic markers and, quite possibly, attractive targets for therapeutic intervention.
METHODS
Gene set compilation. Gene sets were collected directly from indicated publications ( Table 1) . We included all genes for which we could convert the original gene identifiers into Entrez Gene IDs. Full gene-set lists are in Supplementary Table 1 . We constructed three gene sets of proliferation-associated genes (Supplementary Table 3) : the first includes genes functionally associated with cell-cycle progression and cell division according to Gene Ontology (GO) annotations; the second includes cycling genes and was extracted from Whitfield et al. 40 ; and the third includes the tumor-based 'proliferation cluster' and was extracted from Hu et al. 35 . Where indicated, we eliminated these genes from our ES gene sets.
Expression data pre-processing. We imported expression data from the referenced studies. Raw data was downloaded from the NCBI GEO website or from websites indicated in the original publications and processed as previously described 18 . Briefly, we first log 2 transformed the expression values and then calculated the mean expression level for each gene across all samples in a given dataset. These mean values were subtracted from all data points, such that expression was represented relative to the mean of each gene, negative values representing below-mean expression and vice versa. To construct the breast cancer compendium, we first normalized each of the six included studies independently, and then concatenated these sets. In cases where the same individuals were included in more than one of the six studies comprising the compendium, such redundancy was eliminated so that each individual was included only once in the compendium. Specifically, individuals of the Uppsala cohort analyzed in the Miller 30 set were eliminated from the Sotiriou 29 and Desmedt 33 sets, and individuals of the Oxford cohort present in the Sotiriou set were eliminated from the Desmedt set. The normalized expression data files as well as sample annotations can be found online (see URLs section below).
Analysis of gene-set enrichment patterns.
To identify gene-set enrichment patterns we used methods described previously 18 , applied using the Genomica software (see URLs section below). For each sample (array), we first scored the genes whose expression was at least twofold above or below the mean expression level. We then assessed the fraction of over-or underexpressed genes that belong to each tested gene set, calculating a P value according to the hypergeometric distribution. This was repeated for every sample, using a threshold of P < 0.05 for significant enrichment. To compare enrichment patterns across sample groups, we included clinical annotations for each individual sample (such as tumor grade, size and ER status) derived from the original publications. For all samples showing enrichment for a particular gene set, we calculated the fraction of samples that possessed each annotation, and assigned a P value according to the hypergeometric distribution. We used a more stringent threshold, P < 0.01, for this calculation. Heat maps showing gene-set enrichments in individual samples include only those samples enriched for at least one set.
Classification of compendium samples to intrinsic subtypes. We used a published method 35, 48 to classify the 1,211 breast cancer samples in the compendium into the five intrinsic subtypes. This method uses 306 classifying genes whose expression in each of the five subtypes is represented in centroids derived from a training set of breast cancers. A small number of the classifying genes were included in some of our gene sets; elimination of these genes from our gene sets did not substantially affect gene-set enrichment patterns (data not shown).
Survival analysis. All survival data were extracted from the original publications. We defined individual tumors as possessing an ES signature for this purpose if they were enriched for both overexpression of the ES exp1 set and underexpression of the PRC2 targets set, and as possessing a non-ES signature if they showed the opposite enrichments. P values were calculated using the log rank test individuals. Meta-analysis of the overall survival of affected individuals from the five studies indicated was done by combining the log hazard ratio estimated for each study, weighting by inverse estimator variance according to the random effects procedure of DerSimonian and Laird 49 . We eliminated individuals of the Karolinska Institute cohort from the Desmedt 33 set to avoid overlap with other sets. Analyses were done using R package version 0.8-2, Guido Schwarzer (2007) meta: Meta-Analysis (see URLs section below).
Analysis of transcription factor expression. We compiled a set of 68 transcription factors and specific chromatin modifiers included in the NOS TFs, ES exp1 and ES exp2 gene sets (Supplementary Table 4) . Hierarchical clustering was done on the expression values of these genes in the breast cancer compendium dataset using the R module pvclust 50 , with multiscale bootstrap resampling of 10,000 iterations to assess statistical significance, represented by a 1-100 score (Supplementary Fig. 4b ). Clustering was done using the average agglomeration method with correlation as the distance metric. This analysis identified a cluster of nine genes showing coordinated expression associated with poor breast tumor differentiation. We searched for additional transcription regulators showing a similar expression pattern in the breast cancer compendium by calculating the Pearson correlation coefficient of each of 1,700 transcription regulators in the human genome to the mean expression levels of the original 9-gene cluster. Statistical significance was assessed as P < 10 −8 by reshuffling (10 6 iterations) of sample-gene associations.
URLs. http://jura.wi.mit.edu/bioc/benporath/; Genomica software, http:// genomica.weizmann.ac.il/; R meta-analysis package, http://cran.r-project.org.
Note: Supplementary information is available on the Nature Genetics website. Table 5) . Shown are the top-ranking 100 genes, in rank order (top down).
